论文部分内容阅读
玻璃体腔注射bevacizumab治疗多种新生血管性眼病的短期疗效较好,但随着对其研究的不断深入,由玻璃体腔注射的操作过程以及bevacizumab毒性作用等原因引起的一些眼部及全身并发症已逐渐成为临床中不可忽视的问题。就玻璃体腔注射bevacizumab临床应用中出现的并发症,如眼内炎、非感染性眼内炎症反应、一过性眼压升高、结膜下出血、球结膜水肿、视网膜色素上皮(RPE)撕裂、视网膜色素上皮脱离(RPED)、血栓性疾病及子宫不规则出血等进行综述。
The short-term efficacy of intravitreal bevacizumab in the treatment of a variety of neovascular ocular diseases is good, but with the deepening of its research, some ocular and systemic complications that have been caused by intravitreal injection procedures and the toxic effects of bevacizumab Gradually become a clinical problem can not be ignored. Intravitreal complications such as endophthalmitis, noninfectious intraocular inflammation, transient elevated intraocular pressure, subconjunctival hemorrhage, bulbar conjunctival edema, retinal pigment epithelial (RPE) tear, intravitreal injection of bevacizumab , Retinal pigment epithelial detachment (RPED), thrombotic diseases and irregular uterine bleeding were reviewed.